Two medications used to treat depression, bupropion and nortriptyline, help smokers who are trying to quit. Trials of bupropion (Zyban) for smoking cessation indicate that it can double the chance. Review question. We reviewed the evidence on the effects of the drug bupropion in adults with ADHD. We also reviewed adverse effects (side effects experienced as a result of taking the drug). Plain language summary. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Review question. We reviewed the evidence on the effects of the drug bupropion in adults with ADHD. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Review question. We reviewed the evidence on the effects of the drug bupropion in adults with ADHD. (2004) for bupropion SR articles from the Cochrane Review of antidepressants for smoking cessation that were included in the review but not cited in the text and see Silagy et al. (2004) for articles from the Cochrane Review of nicotine replacement therapy that were included in the review but not cited in the text NRT and bupropion helped about 80% more people to quit than placebo; this means that for every 10 people who quit with placebo about 18 could be expected to quit with NRT or with bupropion. Varenicline more than doubled the chances of quitting compared with placebo, so that for every 10 who quit with placebo about 28 could be expected to quit with varenicline. Home » Posts » Mental health » substance misuse » New Cochrane review finds that NRT, bupropion and varenicline are effective treatments for smoking cessation NRT, bupropion, varenicline and cytisine have been shown to improve the chances of quitting. Combination NRT and varenicline are equally effective as quitting aids. Nortriptyline also improves the chances of quitting. On current evidence, none of the treatments appear to have an incidence of adverse A Cochrane review on the use of extended-release bupropion for the treatment of seasonal affective disorder found that bupropion is effective in preventing the recurrence of the disorder; however, four out of five individuals who take the drug will not benefit from treatment and may be at risk for harm. This systematic review and meta-analysis identified 51 studies, dividing into four categories: bupropion as a sole antidepressant, bupropion coprescribed with another antidepressant, bupropion in ‘other’ populations (e.g. bipolar depression, elderly populations) and primary evaluation of side effects.